Glipizide

Introduction Overview

Generic Name

glipizide

Brand Name

Glucotrol

Dosage Form

Oral tablet (immediate-release and extended-release)

Drug Class

Sulfonylureas

Pharmacokinetics

Absorption:
Glipizide is well absorbed following oral administration, with peak plasma concentrations typically attained within 1 to 3 hours after ingestion of immediate-release tablets. The presence of food does not significantly affect the extent of absorption, but it may delay the time to peak concentration. The extended-release formulation is designed to provide a gradual release of the drug, resulting in prolonged plasma concentrations over 24 hours with a more stable pharmacokinetic profile. Absolute bioavailability of glipizide immediate-release tablets is high, reflecting efficient gastrointestinal absorption. Variability in absorption can occur due to individual gastrointestinal motility and pH variations.

Distribution:
Glipizide is extensively bound to plasma proteins, primarily albumin, with a binding rate of approximately 98-99%. This high degree of protein binding limits its volume of distribution, which ranges between 0.13 to 0.2 L/kg. The drug distributes mainly in the plasma and extracellular fluids with limited penetration into the central nervous system and adipose tissues. Protein binding reduces free drug concentrations in plasma but may also result in drug-drug interactions when other highly protein-bound agents are co-administered.

Metabolism:
Glipizide undergoes extensive hepatic metabolism primarily through CYP2C9 isoenzymes to inactive metabolites. The major metabolic pathways include hydroxylation and conjugation. These metabolites do not possess hypoglycemic activity. Hepatic impairment may alter the metabolism of glipizide, potentially increasing plasma levels and prolonging half-life, necessitating dose adjustments. There is minimal first-pass metabolism contributing to systemic availability. Drug interactions affecting CYP2C9 can significantly alter glipizide metabolism.

Elimination:
The elimination half-life of glipizide is approximately 2 to 5 hours for immediate-release formulations and up to 12 hours for extended-release formulations, reflecting sustained absorption. Approximately 80% of the drug and its metabolites are excreted via the urine, with the remainder eliminated in feces. Less than 10% of the drug is excreted unchanged. Renal impairment can result in accumulation of active drug or metabolites, increasing the risk of hypoglycemia. Clearance reductions necessitate careful monitoring and dosing adjustments in patients with compromised renal function. The pharmacokinetic profile supports once or twice daily dosing depending on formulation.

Dosage Forms

Available Dosage Forms:
- Immediate-release oral tablets: 5 mg and 10 mg
- Extended-release oral tablets: 2.5 mg, 5 mg, and 10 mg

Dosages for Adults and Adolescents:
- Initial dose typically starts at 5 mg immediate-release tablet once daily approximately 30 minutes before the first meal of the day.
- Dose adjustments usually occur in increments of 2.5 to 5 mg based on blood glucose response.
- Maximum recommended dose for immediate-release is typically 40 mg per day, divided into one or two doses.
- Extended-release tablets may be initiated at 5 mg orally once daily with breakfast, titrated up to 20 mg once daily dependent on glycemic control.

Specific Patient Populations:
- In elderly patients or those with hepatic or renal impairment, initiate therapy at lower doses (2.5 mg) to reduce hypoglycemia risk.
- Not indicated for treatment of type 1 diabetes or diabetic ketoacidosis.
- Use cautiously in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of hemolysis.
- During pregnancy, glipizide should generally be avoided, especially in the last two weeks, as other agents like insulin are preferred.
- Breastfeeding safety is not established; risk-benefit must be assessed by healthcare provider.

Mechanism Of Action

Glipizide is a second-generation sulfonylurea that primarily exerts its antihyperglycemic effect by stimulating pancreatic beta cells to produce and release insulin. It binds to specific sulfonylurea receptors (SUR1) located on the ATP-sensitive potassium channels (K_ATP) on the beta-cell membrane. This binding results in closure of the K_ATP channels, leading to cell membrane depolarization.

The membrane depolarization triggers opening of voltage-dependent calcium channels, increasing intracellular calcium concentrations. The elevated calcium induces exocytosis of insulin-containing secretory granules into the bloodstream. This sequence effectively increases circulating insulin levels, thereby reducing blood glucose concentration by promoting cellular glucose uptake and storage.

In addition to insulin secretion stimulation, glipizide may increase the sensitivity of peripheral tissues to insulin, improving glucose utilization. However, its primary mechanism remains the enhancement of insulin release from pancreatic beta cells rather than insulin sensitization.

Comparatively, sulfonylureas like glipizide differ mechanistically from other antidiabetic agents such as metformin, which primarily decrease hepatic gluconeogenesis, or thiazolidinediones that act as insulin sensitizers via peroxisome proliferator-activated receptor gamma (PPARγ) activation. Clinical studies demonstrate glipizide’s efficacy in controlling postprandial and fasting blood glucose in type 2 diabetes mellitus, with a rapid onset of action post-administration. However, risks such as hypoglycemia are associated with its insulinotropic effect, necessitating tailored dosing and careful monitoring.

Pharmacological Actions

Stimulates pancreatic beta-cell insulin secretion through sulfonylurea receptor binding and K_ATP channel inhibition.
Lowers blood glucose levels by enhancing insulin-mediated glucose uptake in peripheral tissues.
Improves glycemic control in type 2 diabetes mellitus when combined with diet and exercise.
Exhibits a rapid onset of hypoglycemic action within 30 minutes to 1 hour post-oral administration.
Demonstrates drug efficacy in lowering both fasting and postprandial plasma glucose levels.
Increases sensitivity of peripheral tissues to insulin to a minor extent.
Reduces glycated hemoglobin (HbA1c) levels by approximately 1-2% with chronic use.
Displays prolonged effect with extended-release formulations for once-daily dosing.
Possesses a well-established safety and efficacy profile as a second-generation sulfonylurea.
Metabolized to inactive compounds, minimizing accumulation risk in normal hepatic function.
Exerts negligible extrapancreatic effects compared to insulin sensitizers.
Can produce hypoglycemia as an adverse pharmacodynamic effect due to increased insulin secretion.
Demonstrates clinical benefit in improving beta-cell function and insulin reserve in early type 2 diabetes.
Does not cause weight loss; may contribute to weight gain due to increased insulin levels.
No direct effect on glucagon secretion or hepatic glucose production.

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus to improve glycemic control in adult patients.
Used as monotherapy or in combination with other oral hypoglycemic agents or insulin.
Adjunct to diet and exercise interventions for blood sugar regulation.
Control of fasting and postprandial hyperglycemia in type 2 diabetes.
Alternative oral antidiabetic agent for patients intolerant or contraindicated to metformin.
Treatment in patients inadequately controlled by lifestyle modifications alone.
Option for glycemic control among sulfonylurea group drugs with established efficacy.
Used to reduce risk of diabetes-related complications by lowering blood glucose levels.
Therapeutic choice in patients without renal insufficiency or significant hepatic dysfunction.
May be employed in initial type 2 diabetic patients with mild hyperglycemia.
Pharmacotherapy adjunct in metabolic syndrome patients with impaired glucose tolerance.
Can be used to improve insulin secretory response in early-stage type 2 diabetes.
Useful in patients needing relatively rapid glycemic correction due to potent insulinotropic effect.
Selected for cost-effective diabetes management due to generic availability.
Occasionally considered in elderly diabetic patients with careful dosing adjustments.

Side Or Adverse Effects

Hypoglycemia is the most significant adverse effect, manifesting as headache, sweating, hunger, dizziness, irritability, tremors, nausea, and rapid heartbeat.
Gastrointestinal disturbances including diarrhea, constipation, and abdominal gas.
Central nervous system effects such as dizziness and drowsiness.
Cutaneous reactions including rash, redness, itching, or photosensitivity.
Rare occurrence of hematologic effects such as leukopenia, thrombocytopenia, or hemolytic anemia.
Weight gain due to increased insulin levels may occur.
Potential for allergic reactions including urticaria, angioedema, and in rare cases, anaphylaxis.
Possible elevation of liver enzymes indicating hepatotoxicity, though uncommon.
Taste disturbances have been reported infrequently.
Rare instances of cholestatic jaundice.
Fluid retention and edema in susceptible individuals.
Overdose can lead to severe and prolonged hypoglycemia requiring emergency intervention.
Risk of photosensitive skin reactions with sun exposure.
May exacerbate or precipitate glucose-6-phosphate dehydrogenase deficiency-related hemolysis.
Long-term use may contribute to diminished beta-cell function.

Precautions

Use cautiously in patients with liver or kidney impairment due to altered drug metabolism and excretion.
Closely monitor in patients with a history of severe hypoglycemia or those at high risk.
Avoid in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of hemolysis.
Not recommended for use in type 1 diabetes or diabetic ketoacidosis.
Adjust dosage in the elderly who may have reduced drug clearance and increased sensitivity.
Pregnant women should avoid glipizide especially in the last two weeks of pregnancy; insulin is preferred.
Breastfeeding safety has not been established; consult healthcare provider before use.
Patients should be advised to carry quick sources of glucose to treat hypoglycemia.
Avoid alcohol intake as it can potentiate hypoglycemic effects and cause disulfiram-like reactions.
Patients should inform healthcare providers about all medications to avoid drug interactions.
Close monitoring of blood glucose is essential during periods of stress, illness, or surgery.
Dose adjustments may be needed during significant changes in diet, exercise, or concomitant medications.
Patients should report signs of allergic reactions immediately.
Glipizide tablets with non-absorbable shells may be excreted in stool; this is not harmful.
Avoid abrupt discontinuation without physician consultation.

Warnings

Do not use glipizide in patients with diabetic ketoacidosis; this is a medical emergency requiring insulin.
Severe hypoglycemia can occur and may be life-threatening if not promptly treated.
Use with caution in hepatic or renal dysfunction as drug clearance may be impaired.
Risk of cross-reactivity in patients allergic to sulfonamide antibiotics.
Patients should be warned about symptoms of hypoglycemia and how to treat it promptly.
Avoid alcohol consumption during treatment due to risk of disulfiram-like effects and hypoglycemia.
Not approved for use in pediatric patients due to lack of established safety and efficacy.
Careful monitoring is advised when switching between immediate-release and extended-release formulations to avoid dosing errors.
Prolonged hypoglycemia may require emergency treatment with glucagon injection or intravenous glucose.
In pregnancy, avoid glipizide particularly near term due to fetal risk.
Inform patients on the possibility of non-absorbable tablet shell passage in stool to prevent unnecessary concern.
Use caution when multiple medications affecting blood glucose are administered concurrently.
Careful titration and adjustment needed to prevent overtreatment and hypoglycemia.
Advise patients on signs of allergic reactions; discontinue drug immediately if serious hypersensitivity develops.
Therapy discontinuation should be gradual and medically supervised to prevent glycemic instability.

Contraindication

Known hypersensitivity or allergy to glipizide or other sulfonylurea agents.
Diabetic ketoacidosis, with or without coma; requires insulin treatment.
Type 1 diabetes mellitus as glipizide requires functioning pancreatic beta cells.
Severe hepatic impairment predisposing to altered metabolism.
Severe renal impairment or failure without careful dose adjustment and close monitoring.
Patients with a history of sulfonamide-induced hemolytic anemia or G6PD deficiency.
Pregnancy, especially last trimester, due to risk to fetus.
Breastfeeding women unless benefits outweigh risks and under strict medical supervision.
Concomitant use with drugs that cause severe hypoglycemia without appropriate monitoring.
Patients experiencing acute illness or surgery where glycemic control requires insulin.
Known presence of hypersensitivity to any component in the formulation.
Use in patients with porphyria is generally not advised due to possible exacerbations.

Drug Interactions

Alcohol can potentiate the hypoglycemic effects of glipizide, and may induce a disulfiram-like reaction.
Concomitant use with insulin or other antidiabetic agents increases risk of hypoglycemia.
Drugs that inhibit hepatic enzymes (e.g., cimetidine, fluconazole) may increase glipizide plasma levels leading to hypoglycemia.
Enzyme inducers such as rifampin and carbamazepine can decrease glipizide effectiveness by increasing metabolism.
Beta-blockers may mask symptoms of hypoglycemia such as tachycardia and tremors.
Thiazide diuretics and corticosteroids may antagonize the blood glucose lowering effects of glipizide.
Warfarin and other anticoagulants can have altered effects; monitor coagulation parameters closely.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate hypoglycemia.
Monoamine oxidase inhibitors (MAOIs) can enhance hypoglycemic effects.
Herbal products like ginseng or fenugreek may impact blood glucose control.
High-dose aspirin may increase hypoglycemic effect due to displacement from protein binding sites.
Drugs affecting CYP2C9 enzyme can influence glipizide metabolism and plasma concentrations.
Sulfonamide antibiotics may cross-react and potentiate hypoglycemia.
Drugs that impair renal function may increase risk of drug accumulation and side effects.
Concurrent use with lithium may decrease lithium clearance leading to toxicity.

Preparations Of The Drug

Glucotrol (immediate-release tablet): available in 5 mg and 10 mg strengths.
Glucotrol XL (extended-release tablets): available in 2.5 mg, 5 mg, and 10 mg strengths.
Tablets are film-coated to facilitate swallowing and protect the drug substance.
Immediate-release tablets are advised to be taken 30 minutes before meals.
Extended-release tablets intended for once daily administration with breakfast or the first meal.
Manufactured under strict quality controls to ensure dose uniformity and bioavailability.
Refill formulations are typically supplied in blister packs or bottles.
Shelf life generally 2 to 3 years when stored at room temperature away from moisture and light.
Generic formulations widely available with equivalence to brand formulations.
Some formulations may include non-absorbed tablet shell components that may be seen in stool.
Packaging includes patient information leaflets detailing dosing, side effects, and precautions.
Storage recommendations: store at controlled room temperature 20-25°C (68-77°F).
Supplied for oral administration only; not formulated for parenteral use.
Avoid exposure to excessive heat or humidity which may degrade drug potency.
FDA-approved labeling includes extensive prescribing information and patient counseling materials.